Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Wulff H, Zhorov BS.

Chem Rev. 2008 May;108(5):1744-73. doi: 10.1021/cr078234p. Review. No abstract available.

2.

Neuronal and Cardiovascular Potassium Channels as Therapeutic Drug Targets: Promise and Pitfalls.

Humphries ES, Dart C.

J Biomol Screen. 2015 Oct;20(9):1055-73. doi: 10.1177/1087057115601677. Epub 2015 Aug 24. Review.

3.

Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment?

Wang J, Xiang M.

Pharmacotherapy. 2013 May;33(5):515-28. doi: 10.1002/phar.1236. Epub 2013 Apr 5. Review.

PMID:
23649812
4.

The therapeutic potential of neuronal KCNQ channel modulators.

Gribkoff VK.

Expert Opin Ther Targets. 2003 Dec;7(6):737-48. Review.

PMID:
14640909
5.

The Ca2+-activated K+ channel of intermediate conductance:a possible target for immune suppression.

Jensen BS, Hertz M, Christophersen P, Madsen LS.

Expert Opin Ther Targets. 2002 Dec;6(6):623-36. Review.

PMID:
12472376
6.

Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.

Hofer MJ, Campbell IL.

Br J Pharmacol. 2016 Feb;173(4):716-28. doi: 10.1111/bph.13175. Epub 2015 Jun 12. Review.

7.

Potassium channels as therapeutic targets for autoimmune disorders.

Wulff H, Beeton C, Chandy KG.

Curr Opin Drug Discov Devel. 2003 Sep;6(5):640-7. Review.

PMID:
14579513
8.

K(+) channels as therapeutic targets in oncology.

Stühmer W, Pardo LA.

Future Med Chem. 2010 May;2(5):745-55. doi: 10.4155/fmc.10.24. Review.

PMID:
21426201
9.

Potassium channels: a review of broadening therapeutic possibilities for neurological diseases.

Maljevic S, Lerche H.

J Neurol. 2013 Sep;260(9):2201-11. doi: 10.1007/s00415-012-6727-8. Epub 2012 Nov 11. Review.

PMID:
23142946
10.

The potential therapeutic role of potassium channel modulators in asthma and chronic obstructive pulmonary disease.

Malerba M, Radaeli A, Mancuso S, Polosa R.

J Biol Regul Homeost Agents. 2010 Apr-Jun;24(2):123-30.

PMID:
20487625
11.

ATP sensitive potassium channels: potential drug targets in neuropsychopharmacology.

Gehlert DR, Robertson DW.

Prog Neuropsychopharmacol Biol Psychiatry. 1994 Nov;18(7):1093-102. Review.

PMID:
7846282
12.

The use of aminopyridines in neurological disorders.

Sedehizadeh S, Keogh M, Maddison P.

Clin Neuropharmacol. 2012 Jul-Aug;35(4):191-200. doi: 10.1097/WNF.0b013e31825a68c5. Review.

PMID:
22805230
13.

Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.

Beeton C, Pennington MW, Norton RS.

Inflamm Allergy Drug Targets. 2011 Oct;10(5):313-21. Review.

14.

Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease.

Han S, Yi H, Yin SJ, Chen ZY, Liu H, Cao ZJ, Wu YL, Li WX.

J Biol Chem. 2008 Jul 4;283(27):19058-65. doi: 10.1074/jbc.M802054200. Epub 2008 May 14.

15.

[Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers].

Devaux J, Beeton C, Béraud E, Crest M.

Rev Neurol (Paris). 2004 May;160(5 Pt 2):S16-27. French.

PMID:
15269656
16.

[Levamisole--an attempt at immunomodulating treatment of inflammatory and autoimmune nervous system diseases].

Cendrowski W.

Pol Tyg Lek. 1977 Aug 1;32(31):1211-3. Review. Polish. No abstract available.

PMID:
331285
17.

Potassium channels in T lymphocytes: therapeutic targets for autoimmune disorders?

Vianna-Jorge R, Suarez-Kurtz G.

BioDrugs. 2004;18(5):329-41. Review.

PMID:
15377175
18.

Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.

Norton RS, Pennington MW, Wulff H.

Curr Med Chem. 2004 Dec;11(23):3041-52. Review.

PMID:
15578998
19.

Research into the therapeutic roles of two-pore-domain potassium channels.

Es-Salah-Lamoureux Z, Steele DF, Fedida D.

Trends Pharmacol Sci. 2010 Dec;31(12):587-95. doi: 10.1016/j.tips.2010.09.001. Epub 2010 Oct 15. Review.

PMID:
20951446
20.

Modulation of potassium channels as a therapeutic approach.

Lawson K, McKay NG.

Curr Pharm Des. 2006;12(4):459-70. Review.

PMID:
16472139

Supplemental Content

Support Center